Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Follow-Up Questions
Who is the CEO of Tectonic Therapeutic Inc?
Dr. Alise Reicin is the President of Tectonic Therapeutic Inc, joining the firm since 2024.
What is the price performance of TECX stock?
The current price of TECX is $15.28, it has increased 2% in the last trading day.
What are the primary business themes or industries for Tectonic Therapeutic Inc?
Tectonic Therapeutic Inc belongs to Biotechnology industry and the sector is Health Care
What is Tectonic Therapeutic Inc market cap?
Tectonic Therapeutic Inc's current market cap is $285.9M
Is Tectonic Therapeutic Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Tectonic Therapeutic Inc, including 3 strong buy, 10 buy, 1 hold, 0 sell, and 3 strong sell
